Involvement of hyaluronan and its receptor CD44 with choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 9, 2009, Pages 4410-4415

  Mochimaru, Hiroshi ^a   Takahashi, Eri ^a,b   Tsukamoto, Nobuo ^a   Miyazaki, Junichiro ^a   Yaguchi, Tomonori ^a   Koto, Takashi ^a   Kurihara, Toshihide ^a   Noda, Kousuke ^a   Ozawa, Yoko ^a   Ishimoto, Takatsugu ^a   Kawakami, Yutaka ^a   Tanihara, Hidenobu ^b   Saya, Hideyuki ^a   Ishida, Susumu ^a   Tsubota, Kazuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; HYALURONIC ACID SYNTHASE; HYMECROMONE; MESSENGER RNA; NEUTRALIZING ANTIBODY; SYNTHETASE; UNCLASSIFIED DRUG; 4-METHYLUMBELLIFERONE; BLOCKING ANTIBODY; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; HYALURONAN SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DNA MICROARRAY; IMMUNOHISTOCHEMISTRY; LASER COAGULATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION; ANIMAL; C57BL MOUSE; CHOROID; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD44; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION PROFILING; GLUCURONOSYLTRANSFERASE; HYALURONIC ACID; HYMECROMONE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70349232405     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3044     Document Type: Article

References (43)

1. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36:182-191.
2. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;114:464-472.
3. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353-363.
4. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
6. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578-3585.
7. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol. 2003;74:25-32.
8. Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:2743-2749.
9. Nagai N, Oike Y, Izumi-Nagai K, et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol. 2006;26:2252-2259.
10. Nagai N, Oike Y, Izumi-Nagai K, et al. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest Ophthalmol Vis Sci. 2007;48: 2321-2326.
11. Izumi-Nagai K, Nagai N, Ozawa Y, et al. Interleukin-6 receptormediated activation of signal transducer and activator of transcription- 3 (STAT3) promotes choroidal neovascularization. Am J Pathol. 2007;170:2149-2158.
12. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435-461.
13. Knudson W, Chow G, Knudson CB. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol. 2002;21:15-23.
14. Camp RL, Scheynius A, Johansson C, Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J Exp Med. 1993;178:497-507.
15. Pure E, Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med. 2001;7:213-221.
16. Zeidler A, Brauer R, Thoss K, et al. Therapeutic effects of antibodies against adhesion molecules in murine collagen type II-induced arthritis. Autoimmunity. 1995;21:245-252.
17. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A. 1999;96:6896-6901.
18. Rafi-Janajreh AQ, Chen D, Schmits R, et al. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J Immunol. 1999;163:1619-1627.
19. Wang X, Xu L, Wang H, Zhan Y, Pure E, Feuerstein GZ. CD44 deficiency in mice protects brain from cerebral ischemia injury. J Neurochem. 2002;83:1172-1179.
20. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science. 2002;296:155-158.
21. Chen H, Liu B, Lukas TJ, Neufeld AH. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS ONE. 2008;3:e2339.
22. Farjo R, Peterson WM, Naash MI. Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0. Invest Ophthalmol Vis Sci. 2008;49:511-521.
23. Chowers I, Wong R, Dentchev T, et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47:2135-2140.
24. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem. 2006;96:706-718.
25. Izumi-Nagai K, Nagai N, Ohgami K, et al. Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler Thromb Vasc Biol. 2007;27:2555-2562.
26. Yoshihara S, Kon A, Kudo D, et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett. 2005;579:2722-2726.
27. Hajime M, Shuichi Y, Makoto N, et al. Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer. 2007;120:2704-2709.
28. Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999;42:659-668.
29. Lambert V, Wielockx B, Munaut C, et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003;17:2290-2292.
30. Fu Y, Ponce ML, Thill M, Yuan P, Wang NS, Csaky KG. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci. 2007;48:5184-5190.
31. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ. Involvement of CD44 in leukocyte trafficking at the bloodretinal barrier. J Leukoc Biol. 2002;72:1133-1141.
32. Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol. 1998;82:1063-1071.
33. Murata M, Horiuchi S. Hyaluronan synthases, hyaluronan and its CD44 receptors in the posterior segment of rabbit eye. Ophthalmologica. 2005;219:287-291.
34. Kudo D, Kon A, Yoshihara S, et al. Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem Biophys Res Commun. 2004; 321:783-787.
35. Kakizaki I, Kojima K, Takagaki K, et al. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem. 2004;279:33281-33289.
36. Nedvetzki S, Gonen E, Assayag N, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A. 2004;101:18081-18086.
37. Slevin M, Krupinski J, Gaffney J, et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2007;26:58-68.
38. Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res. 2006;83:1325-1334.
39. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis. 2003;9:747-755.
40. Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H, Honda Y. Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina. 2005;25:911-918.
41. Gamulescu MA, Chen Y, He S, et al. Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res. 2006;83:212-222.
42. Casaroli-Marano RP, Pagan R, Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40:2062-2072.
43. Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci. 1995;36:391-405.